Heron Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Heron Therapeutics

25/02/2025 14:05

Heron Therapeutics Inc HRTX.OQ HRTX.O is expected to show a rise in quarterly revenue when it reports  results on February 27 for the period ending December 31 2024

The San Diego California-based  company is expected to report a 9.2% increase in revenue to $37.367 million from $34.23 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on November 12 2024, for the period ended December 31, was for revenue between $37.00 million and $43.00 million.

‚ÄčLSEG's mean analyst estimate for Heron Therapeutics Inc is for a loss of 3 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00‚Äč, above‚Äč its last closing price of $1.77. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.03
-0.03
-0.03
Met
10
Jun. 30 2024
-0.04
-0.04
-0.06
Missed
-50
Mar. 31 2024
-0.08
-0.09
-0.02
Beat
77.8‚Äč
Dec. 31 2023
-0.16
-0.16
-0.07
Beat
57.2
‚Äč‚ÄčSep. 30 2023
-0.29
-0.29
-0.17
Beat
41.9
Jun. 30 2023
-0.23
-0.23
-0.35
Missed
-50‚Äč
Mar. 31 2023
-0.21
-0.20
-0.27
Missed
-33
Dec. 31 2022
-0.30
-0.28
-0.17
Beat
40.4

This summary was machine generated February 25 at 14:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)